Eric Mortensen - Cytosorbents Crp Chief Medical Officer
| CTSO Stock | USD 0.80 0.07 8.05% |
Executive
Dr. Eric G. Mortensen is the Chief Medical Officer of the Company. Dr. Mortensen received an A.B. in Biochemistry fromHarvard College, an M.D. from theHarvard Universityand Massachusetts Institute of Technology Division of Health Sciences and Technology, and a Ph.D. in Biophysics at theHarvard Graduate School of Arts and Scienceswhere he studied the transduction of membranebound hormone receptor binding into intracellular activation of metabolic activity and cellular proliferation. Dr. Mortensen completed an internship and residency in Internal Medicine at the Massachusetts General Hospital and a fellowship in Gastroenterology at theUniversity of MichiganMedical Center, Ann Arbor. since 2017.
| Tenure | 7 years |
| Address | 305 College Road East, Princeton, NJ, United States, 08540 |
| Phone | 732 329 8885 |
| Web | https://www.cytosorbents.com |
Cytosorbents Crp Management Efficiency
The company has return on total asset (ROA) of (0.3248) % which means that it has lost $0.3248 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9721) %, meaning that it created substantial loss on money invested by shareholders. Cytosorbents Crp's management efficiency ratios could be used to measure how well Cytosorbents Crp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of April 2024, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to grow to -0.75. At this time, Cytosorbents Crp's Total Assets are very stable compared to the past year. As of the 17th of April 2024, Non Current Assets Total is likely to grow to about 28.9 M, while Total Current Assets are likely to drop about 17.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kim Sullivan | Encompass Health Corp | N/A | |
| Bridget Sherick | Select Medical Holdings | N/A | |
| John Duggan | Select Medical Holdings | N/A | |
| Shelly Eckenroth | Select Medical Holdings | N/A | |
| Dylan Black | Enhabit | 54 | |
| Mark Brewer | Enhabit | N/A | |
| Anderson Sr | National HealthCare | 62 | |
| Oleg Mikulinsky | CryoCell International | 51 | |
| Kirk Cheney | Pennant Group | N/A | |
| Mary Lacey | Select Medical Holdings | N/A | |
| Langham MBA | Enhabit | 47 | |
| MS DO | Encompass Health Corp | 64 | |
| Elissa Charbonneau | Encompass Health Corp | 64 | |
| Cheryl Levy | Encompass Health Corp | 58 | |
| RN BSN | Enhabit | 66 | |
| Andrew Price | Encompass Health Corp | 57 | |
| Brian Rusignuolo | Select Medical Holdings | 48 | |
| Lynette CPA | Pennant Group | 47 | |
Management Performance
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.32 |
Cytosorbents Crp Leadership Team
Elected by the shareholders, the Cytosorbents Crp's board of directors comprises two types of representatives: Cytosorbents Crp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytosorbents. The board's role is to monitor Cytosorbents Crp's management team and ensure that shareholders' interests are well served. Cytosorbents Crp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytosorbents Crp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Bloch, CFO | ||
| CPA CPA, CFO Sec | ||
| Alan Sobel, Director | ||
| Michael Bator, Director | ||
| Phillip Chan, President CEO, Director | ||
| MS MS, Pres COO | ||
| Christian MD, Executive Marketing | ||
| Vincent MS, President COO | ||
| FACC FESC, Chief Officer | ||
| Vincent Capponi, COO | ||
| James Gunton, Independent Director | ||
| Jodi Hoover, Executive | ||
| Robert MD, CoChairman Consultant | ||
| Edward Jones, Independent Director | ||
| MS MBA, Senior Development | ||
| Terri MBA, Vice Communications | ||
| Irina Kulinets, Senior Affairs | ||
| Eric Mortensen, Chief Medical Officer | ||
| Al Kraus, Chairman of the Board | ||
| Robert Bartlett, Chief Medical Officer |
Cytosorbents Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytosorbents Crp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.32 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 51.24 M | ||||
| Shares Outstanding | 54.29 M | ||||
| Shares Owned By Insiders | 9.75 % | ||||
| Shares Owned By Institutions | 39.57 % | ||||
| Number Of Shares Shorted | 1.62 M | ||||
| Price To Earning | (16.30) X |
Pair Trading with Cytosorbents Crp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.Moving against Cytosorbents Stock
| 0.53 | PNTG | Pennant Group Financial Report 2nd of May 2024 | PairCorr |
| 0.47 | GCTK | GlucoTrack | PairCorr |
| 0.45 | EHAB | Enhabit Financial Report 14th of May 2024 | PairCorr |
| 0.41 | ADUS | Addus HomeCare Financial Report 6th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.
The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Cytosorbents Stock analysis
When running Cytosorbents Crp's price analysis, check to measure Cytosorbents Crp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Crp is operating at the current time. Most of Cytosorbents Crp's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Crp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytosorbents Crp's price. Additionally, you may evaluate how the addition of Cytosorbents Crp to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Cytosorbents Crp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 0.814 | Quarterly Revenue Growth (0.08) | Return On Assets (0.32) | Return On Equity (0.97) |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.